Teva's investment in Andromeda will fund diabetes treatment

JERUSALEM Teva Pharmaceutical Industries has invested $11.9 million in Andromeda Biotech, a company that develops diabetes drugs, according to published reports.

In addition, Andromeda parent company Clal Biotechnology Industries will invest another $5.6 million. The two investments will result in Teva having a 16% stake in Andromeda and Clal having an 84% stake.

Andromeda will use the money from the investment to fund development of DiaPep277, a Type 1 diabetes treatment in late-stage clinical studies for which the company hopes to gain regulatory approval in the United States and Europe. The drug is designed to prevent destruction of insulin-producing cells in the pancreas in patients who still have some of the cells remaining and is considered the first drug to work in this way.

Login or Register to post a comment.